On Jan. 30, both the House Oversight and Reform Committee and the Senate Finance Committee held a hearing on drug prices. These are the first hearing of the 116th Congress that focused on rising drug costs. Drug manufactures declined to participate in both hearings. Issues around the 340B Drug Discount were raised during the Senate hearing. Additionally, both hearings featured a parent advocate that talked about the rising cost of the insulin. Additional hearings on drug prices are expected over the next few months.